mBIOTA Elemental™ Effectively Reduces IMO-Causing Methanogenic Archaea M. smithii

Featured oral presentation at Digestive Disease Week 2025 demonstrates significant modulatory effects of palatable elemental diet on methanogens in managing the gut microbiome beyond just bacteria

SANTA MONICA, Calif.--(BUSINESS WIRE)--mBIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, announces that their flagship product, mBIOTA Elemental™ Diet, has shown effectiveness at managing the gut microbiome beyond just gut bacteria. The first clinically-proven palatable elemental diet, initially studied as a solution for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) as focused on reducing intestinal bacteria and related symptoms of such gastrointestinal disorders, has now been demonstrated to effectively reduce Methanobrevibacter smithii (M. smithii), an abundant methane-producing archaea in humans that is known to cause IMO.

Prospective clinical trial data measuring the presence of M. smithii in individuals with IMO via methane breath testing and stool samples demonstrated a statistically significant decrease in methanogenic archaea. Detected in 61% of participants with IMO at the baseline, M. smithii was either decreased or undetectable in 92% of participants by the end of the study. These findings, as featured at Digestive Disease Week (DDW) 2025 in an oral presentation titled “Reduction Of Breath Methane Levels Correlates With Fecal Abundance Of Methanobrevibacter Smithii Following Two-Weeks Of Exclusive Oral Elemental Diet,” expand upon promising medical use cases of mBIOTA Elemental™ for the management of GI conditions.

“The gut microbiome is filled with more microorganisms than just bacteria. Archaea also play a significant role in how the human gut functions and the gastrointestinal symptoms individuals may experience, such as constipation,” says Dr. Ali Rezaie, medical advisor to mBIOTA Labs and renowned gastroenterologist. “While more research is needed to determine the long-term effects of elemental diet in individuals with IMO, these findings are encouraging for the development of a more targeted solution to manage excess gut archaea.”

“mBIOTA Labs has made great strides in increasing the accessibility of elemental diets by focusing on improving palatability and reinforcing the clinical proof behind mBIOTA Elemental™ for managing the gut microbiome as a whole with peer-reviewed studies. We’re glad to continue the trend with these new positive findings for archaea modulation,” says Nicola Wodlinger, CEO of mBIOTA Labs. “We’re dedicated to offering providers a tool for their patients that targets the root causes of GI conditions to optimize gut health rather than temporarily treating the symptoms. This is one huge step forward for helping IMO patients.”

mBIOTA Labs’ truly palatable elemental diet offers patients an approachable and clinically reliable option to manage GI conditions like SIBO and IMO. For more information on mBIOTA Labs, mBIOTA Elemental™, and related clinical findings, visit www.mBIOTA.com.

About mBIOTA Labs

mBIOTA Labs harnesses proprietary Amino Taste Modification Technology (ATMT) to create clinically proven, science-backed medical foods, designed to optimize gut health and overall well-being. Trusted by the medical community, mBIOTA’s mission is to empower individuals with evidence-based nutrition solutions that enhance quality of life. mBIOTA's award-winning, clinically proven, palatable elemental diet, mBIOTA Elemental™, revolutionizes medical nutrition for the dietary management of GI dysfunction, including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), intestinal methanogen overgrowth (IMO), eosinophilic esophagitis (EoE) and other conditions. For more information on mBIOTA Labs and mBIOTA Elemental™, visit www.mBIOTA.com.